Population Health Research Institute
Study List

CHARM (Completed) 
Candesartan Cilexetil in Heart Failure Assessment of Reduction in Mortality and Morbidity

< back

 

Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall Program.

* Please note this study was not coordinated by PHRI; Dr. Salim Yusuf was a member of the Executive Committee and PI of one of three component trials with significant input in protocol development and overall study design.

Study Design: Randomized double blind parallel group design.

Intervention: Candesartan vs. placebo.

Length of Study: 4 years.

# of Patients: 7,601.

Patient Populations: Chronic Heart Failure.


Presentations

Not available at this time.


Main Publications (for a full listing of publications, please visit the 'Media and Publications' section)

Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J, Yusuf S, Pocock S; CHARM Investigators and Committees.Effects of candesartan on mortality and morbidity in patients with chronic heart failure: the CHARM-Overall programme. Lancet. 2003 Sep 6;362(9386):767-71.

Yusuf S, Pfeffer MA, Swedberg K, Granger CB, Held P, McMurray JJ, Michelson EL, Olofsson B, Ostergren J; CHARM Investigators and Committees. Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: the CHARM-Preserved Trial. Lancet. 2003 Sep 6;362(9386):777-81.

Print    Email
Population Health Research Institute • Hamilton, Ontario • information@phri.ca